Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaBSE:RMAH +0.23%58 Net Margin % is 0.40% as of Mar. 2026, which is 63% below its 10-year median of 1.07. GuruFocus rates BSE:RMAH with a GF Score™ of 58/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 8 warning signs investors should review. Among 117 Medical Distribution companies, Farmaceutica Remedia ranks worse than 65.81% on this metric.
The historical rank and industry rank for Farmaceutica Remedia's Net Margin % or its related term are showing as below:
BSE:RMAH'
s Net Margin % Range Over the Past 10 Years
Min: 0.5 Med: 1.07 Max: 8.56
Current: 0.8
BSE:RMAH's Net Margin % is ranked worse than 65.81% of 117
companies
in the Medical Distribution industry
Industry Median: 1.47
vs BSE:RMAH: 0.80
Farmaceutica Remedia (BSE:RMAH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Farmaceutica Remedia Net Margin % Related Terms
Farmaceutica Remedia Net Margin % Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, CAH, COR: Net Margin % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Net Margin % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a Net Margin % of 0.40% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Farmaceutica Remedia and its competitors. This is 63% below median its historical median of 1.07. Over the past decade, Farmaceutica Remedia's Net Margin % has ranged from 0.50 to 8.56. According to the industry distribution chart, Farmaceutica Remedia ranks #77 out of 117 companies in the Medical Distribution industry, placing it in the top 65.8%.
Is Farmaceutica Remedia's Net Margin % too high?
Farmaceutica Remedia's current Net Margin % of 0.40% is 63% below median its 10-year median of 1.07. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 8.56. The Medical Distribution industry median Net Margin % is 1.47. Farmaceutica Remedia's value of 0.40% is 72.8% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #77 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Net Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #77 out of 117 companies for Net Margin %. This places Farmaceutica Remedia in the lower half of its industry. The industry median Net Margin % is 1.47. Farmaceutica Remedia's value of 0.40% is 72.8% below this benchmark. Historically, Farmaceutica Remedia's own Net Margin % has ranged from 0.50 to 8.56 over the past decade. While the company's 10-year median is 1.07 vs. the industry median of 1.47, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.47, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Net Margin % of 0.40% is 72.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Net Margin % is 0.40%, which is 63% below median its own 10-year median of 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Net Margin % is 0.40%, which is 63% below median its 10-year median of 1.07 and 72.8% below the Medical Distribution industry median of 1.47. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Net Margin % is 0.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
Net Margin %: 0.40% (63% below median its 10-year median of 1.07)
GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
Industry Position: 72.8% below the Medical Distribution median (#77 of 117)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
